Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ghassan Fraij

Interventional Cardiology Tempe, AZ Medical Doctor

NPI 1225253800 CMS profile 191531

1847 E Southern Ave Ste 4, Tempe, AZ 85282

Open in the dashboard

General payments

$10,408

572 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ghassan Fraij of Tempe, AZ is reported in the CMS Open Payments database as having received $10,408 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,376 74
2024 General $1,671 87
2023 General $1,915 99
2022 General $2,262 128
2021 General $1,513 96
2020 General $1,201 64
2019 General $471 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghassan Fraij
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ghassan Fraij were reported at $1,376. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ghassan Fraij Interventional Cardiology median Middle half National median
2019 $471 $1,097 $329–$3,048 $163
2020 $1,201 $473 $161–$1,480 $114
2021 $1,513 $677 $233–$1,827 $132
2022 $2,262 $978 $333–$2,724 $149
2023 $1,915 $1,136 $382–$2,986 $160
2024 $1,671 $1,181 $395–$3,326 $164
2025 $1,376 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,276 76 payments
  2. Amgen Inc. $967 69 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $936 46 payments
  4. Merck Sharp & Dohme Corporation $882 49 payments
  5. Janssen Pharmaceuticals, Inc $679 46 payments
  6. Pfizer Inc. $559 37 payments
  7. AstraZeneca Pharmaceuticals LP $482 25 payments
  8. Abbott Laboratories $464 22 payments
  9. Boston Scientific Corporation $429 15 payments
  10. Novo Nordisk Inc $408 23 payments
  11. Other $3,327 164 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,301 569 payments
  2. Education $91 2 payments
  3. Consulting Fee $16 1 payment
Products named General payments · program years 2019–2025
  1. VERQUVO $1,052 57 payments
  2. LifeVest $936 46 payments
  3. Repatha $815 60 payments
  4. XARELTO $679 46 payments
  5. LEQVIO $512 28 payments
  6. ENTRESTO Cardiovascular $454 32 payments
  7. Ozempic $345 20 payments
  8. VYNDAQEL $322 21 payments
  9. ENTRESTO Cardiology/Vascular Diseases $310 16 payments
  10. ELIQUIS $279 19 payments
  11. Other $5,186 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

8,765

Median for Cardiology: 2,533

Drug cost

$1,737,512

Median for Cardiology: $485,213

Branded share of claims

35.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 785 $679,655
Entresto Sacubitril/Valsartan Brand 592 $531,239
Xarelto Rivaroxaban Brand 225 $207,998
Farxiga Dapagliflozin Propanediol Brand 66 $55,199
Jardiance Empagliflozin Brand 61 $40,653
Repatha Syringe Evolocumab Brand 67 $40,344
Ozempic Semaglutide Brand 29 $28,596
Brilinta Ticagrelor Brand 32 $19,155
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 62 $16,872
Praluent Pen Alirocumab Brand 21 $10,481

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$571,903

Medicare's payments for the services billed

Medicare patients

1,119

Average age 75

Services billed

5,482

555 women, 564 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 45%
Arthritis 45%
Diabetes 41%
Chronic kidney disease 37%
Atrial fibrillation 34%
Heart failure 30%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $187
$187 80 —
VERQUVO
  • Merck Sharp & Dohme Corporation $170
$170 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $158
$158 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $141
$141 592 —
XARELTO
  • Janssen Pharmaceuticals, Inc $92
$92 225 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record